Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.45 |
| ▸ | FAP | Q12884 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL389541 | 0.98 | DPP4 (0.46) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4959205 | 0.81 | DPP4 (0.44) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL14185988 | 0.80 | EPHX1 (0.37) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL2768837 | 0.79 | SLC7A5 (0.42) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL1509633 | 0.78 | SLC7A5 (0.41) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6760294 | 0.78 | CES2 (0.42) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6651288 | 0.78 | CES2 (0.42) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL29779928 | 0.76 | CES2 (0.41) | DPP4DPP7 | |
| SCHEMBL3366847 | 0.76 | HSD11B1 (0.42) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL17599037 | 0.74 | CES2 (0.42) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675578-B9 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2014-06-25 | — | — | EP | claimed |
| EP-1675578-B1 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2013-05-22 | — | — | EP | claimed |
| EP-1620082-B9 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR TREATING ALZHEIMER'S DISEASE AND DOWN SYNDROME | PROBIODRUG AG (DE) | 2010-08-25 | — | — | EP | claimed |
| EP-1620082-B1 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR TREATING ALZHEIMER'S DISEASE AND DOWN SYNDROME | PROBIODRUG AG (DE) | 2010-04-21 | — | — | EP | claimed |
| EP-1599203-B1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES CONTAINING ACIDIC, MAINLY HETEROCYCLIC GROUPS, CORRESPONDING PRODUCTION METHOD AND USE OF SAID DERIVATIVES AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-10-23 | — | — | EP | disclosed |
| EP-1599454-B1 | DIARYLCYCLOALKYL DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-12-26 | — | — | EP | disclosed |
| EP-1841731-B1 | SUBSTITUTED AMINOMETHYLENE SULPHONAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| EP-1893590-B1 | Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors | SANOFI SA (FR) | 2012-08-15 | — | — | EP | disclosed |
| EP-1599443-B1 | CYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-12-21 | — | — | EP | disclosed |
| EP-1713779-B1 | INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE-SENSITIVE LIPASES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-04-13 | — | — | EP | disclosed |
| EP-1601643-B1 | ARYLCYCLOALKYL DERIVATIVES WITH BRANCHED SIDE CHAINS AS PPAR RECEPTOR MODULATORS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-03-30 | — | — | EP | disclosed |
| EP-1896435-B1 | BENZOTHIAZOL-2-ON DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI AVENTIS (FR) | 2011-01-12 | — | — | EP | disclosed |
| WO-2004076401-A1 | CYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004076426-A1 | 3-METHYL-2- (3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXANECARBONYL-AMINO BUTYRIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF TYPE 2 DIABETES AND ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004076402-A1 | ARYLCYCLOALKYL DERIVATIVES WITH BRANCHED SIDE CHAINS AS PPAR RECEPTOR MODULATORS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004076447-A1 | CYCLOALKYL DERIVATIVES COMPRISING BIOISOSTERIC CARBOXYLIC ACID GROUPS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004076428-A1 | 4-(3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXYLOXY)-BUTANE ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR TREATING DIABETES OF TYPE 2 AND ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004076427-A1 | 3-(2-PHENYL-OXAZOL-4-YL METHOXY) CYCLOHEXYLMETHOXY ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS USED AS PPAR MODULATORS FOR TREATING TYPE 2 DIABETES AND ARTERIOSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004075891-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES CONTAINING ACIDIC, MAINLY HETEROCYCLIC GROUPS, CORRESPONDING PRODUCTION METHOD AND USE OF SAID DERIVATIVES AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004075815-A2 | DIARYLCYCLOALKYL DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |